Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
IPO Year:
Exchange: NYSE
Website: cardinalhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $125.00 | Outperform | Leerink Partners |
| 2/9/2024 | Hold → Buy | Argus | |
| 1/3/2024 | $117.00 | Overweight | Barclays |
| 12/14/2023 | $96.00 | Underweight | Wells Fargo |
| 7/10/2023 | $100.00 | Outperform → In-line | Evercore ISI |
| 3/31/2023 | $77.00 | Neutral | Citigroup |
| 2/3/2023 | $87.00 → $94.00 | Neutral → Outperform | Robert W. Baird |
| 11/4/2022 | $64.00 → $80.00 | Underperform → Neutral | BofA Securities |
| 8/22/2022 | $70.00 → $76.00 | Overweight | Morgan Stanley |
| 5/26/2022 | Overweight → Equal Weight | Barclays |
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
144 - CARDINAL HEALTH INC (0000721371) (Subject)
10-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
11-K - CARDINAL HEALTH INC (0000721371) (Filer)
11-K - CARDINAL HEALTH INC (0000721371) (Filer)
SD - CARDINAL HEALTH INC (0000721371) (Filer)
10-Q - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
New facility opening in Walton Hills demonstrates ongoing commitment to increase U.S. warehouse capacity and modernize operations DUBLIN, Ohio, Aug. 21, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today its plans to open a new distribution center in Walton Hills, Ohio, supporting its U.S. Medical Products and Distribution business. The facility will integrate new technology solutions, deliver operational efficiencies, and provide expanded capacity in the Cleveland, Ohio area. With construction underway, the distribution center is anticipated to be fully operational in the spring of 2025 and, at nearly 249,000 square feet, is more than 30% larger than the Cardinal Health locat
DUBLIN, Ohio, Aug. 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2024 to shareholders of record at the close of business on October 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business
Fourth quarter revenue increased 12% to $59.9 billionFourth quarter GAAP1 operating earnings were $401 million and GAAP diluted EPS was $0.96Fourth quarter non-GAAP operating earnings increased 14% to $605 million and non-GAAP diluted EPS increased 29% to $1.84Fiscal Year 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectivelyFiscal year 2025 non-GAAP EPS guidance raised to $7.55 to $7.70, from at least $7.50DUBLIN, Ohio, Aug. 14, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2024 revenues of $59.9 billion, an increase of 12% from the prior year. GAAP operating earnings were $401 m
DUBLIN, Ohio, July 23, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2024 on August 14, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal He
DUBLIN, Ohio, May 7, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 year
Revenue increased 9% to $54.9 billionGAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08Fiscal year 2024 non-GAAP EPS guidance2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50DUBLIN, Ohio, May 2, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were
DUBLIN, Ohio, April 22, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35. Despite the nonrenewal of the OptumRx contracts, the company also reiterated both its Pharmaceutical and Specialty Solutions long-term segment profit CAGR target of 4% to 6% and its consolidated non-GAAP EPS CAGR target of 12% to 14% for fiscal years 2024 to 2026, relative to a fiscal 2023 baseline. Affirming these targets reflects the company's ability to achieve sustained growth over the long term a
The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE:CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business. Located in the Rickenbacker Global Logistics Park, the Consumer Health Logistics Cente
DUBLIN, Ohio, March 26, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardinal Hea
DUBLIN, Ohio, March 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels. "We are committed to reducing our impact on the environment and contributing to a more sustainable world," said Megan Maltenfort, Cardinal Health's VP of Envir
Citigroup analyst Daniel Grosslight maintains Cardinal Health (NYSE:CAH) with a Neutral and lowers the price target from $115 to $107.
Cardinal Health's (NYSE:CAH) short percent of float has fallen 17.69% since its last report. The company recently reported that it has 6.12 million shares sold short, which is 3.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere
Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:CAH) with a In-Line and lowers the price target from $115 to $105.
Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:CAH) with a Outperform and raises the price target from $129 to $130.
First, Claudia Post oversaw the safe delivery of eyeballs, kidneys and other organs. Today? Her specialty is cannabis. Most recently, she launched Scarlet Express with financial backing from Ben Sopranzetti, vice chair of the Department of Finance and Economics at Rutgers Business School. The Philadelphia-based startup is a state-approved, closed-loop delivery organization providing discreet, secure and expert cannabis supply chain management nationwide. And Post is the perfect person for this type of venture. A serial entrepreneur, Post launched MOST Consulting Group, a one-stop shop for cannabis marketing and advertising, and founded Diamond Transportation Group, a same-day, ti
Cardinal Health (NYSE:CAH) has outperformed the market over the past 5 years by 2.37% on an annualized basis producing an average annual return of 15.18%. Currently, Cardinal Health has a market capitalization of $23.86 billion. Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,026.95 today based on a price of $97.96 for CAH at the time of writing. Cardinal Health's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content
Cardinal Health (NYSE:CAH) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 17.8%. Currently, Cardinal Health has a market capitalization of $25.27 billion. Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,305.49 today based on a price of $103.77 for CAH at the time of writing. Cardinal Health's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content
Cardinal Health (NYSE:CAH) has outperformed the market over the past 5 years by 4.09% on an annualized basis producing an average annual return of 17.12%. Currently, Cardinal Health has a market capitalization of $23.86 billion. Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,235.91 today based on a price of $97.96 for CAH at the time of writing. Cardinal Health's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content
Cardinal Health's (NYSE:CAH) short percent of float has fallen 5.36% since its last report. The company recently reported that it has 8.05 million shares sold short, which is 4.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
UnitedHealth Group‘s (NYSE:UNH) OptumRx unit has a new pricing model to help manage drug costs for insurers. Starting next year, the OptumRx Clear Trend Guarantee will offer value-based pricing for drugs. It will integrate costs from various sources such as retail pharmacies, home delivery, specialty drugs, and rebates. Value-based pricing means that payments for medicines will be linked to patient outcomes. This involves insurers, pharmaceutical companies, and pharmacy benefit management (PBMs) like OptumRx. Related: Analysts Raises Forecasts On UnitedHealth On Controlled Growth Strategy After Cyber Hack. This model aims to provide a more transparent and predictable drug pr
DUBLIN, Ohio, Aug. 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2024 to shareholders of record at the close of business on October 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business
Fourth quarter revenue increased 12% to $59.9 billionFourth quarter GAAP1 operating earnings were $401 million and GAAP diluted EPS was $0.96Fourth quarter non-GAAP operating earnings increased 14% to $605 million and non-GAAP diluted EPS increased 29% to $1.84Fiscal Year 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectivelyFiscal year 2025 non-GAAP EPS guidance raised to $7.55 to $7.70, from at least $7.50DUBLIN, Ohio, Aug. 14, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2024 revenues of $59.9 billion, an increase of 12% from the prior year. GAAP operating earnings were $401 m
DUBLIN, Ohio, May 7, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 year
Revenue increased 9% to $54.9 billionGAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08Fiscal year 2024 non-GAAP EPS guidance2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50DUBLIN, Ohio, May 2, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were
DUBLIN, Ohio, Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2024 to shareholders of record at the close of business on April 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, ope
Revenue increased 12% to $57.4 billionGAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35, from $6.75 to $7.002,3Fiscal 2024 non-GAAP adjusted free cash flow guidance raised to ~$2.5 billion, from ~$2.0 billionCardinal Health to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organizationDUBLIN, Ohio, Feb. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal 2024 revenue of $57.4 billion, an increase of 12% from the second
Progress achieved on company's ongoing business and portfolio review Completed review of growth businesses within the Medical Segment: investing in and further developing at-Home Solutions and OptiFreight® Logistics as part of the company's portfolio for long-term growth and value creationReview of Global Medical Products and Distribution business continues, with focus on driving operational performance through the Medical Improvement PlanReorganizing leadership structure to continue company's simplification efforts, prioritize core operational execution and drive efficiencies, accountability and transparencyUpdated enterprise operating and segment reporting structure, effective January 1, 2
DUBLIN, Ohio, Nov. 14, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2024 to shareholders of record at the close of business on January 2, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in busines
Fourth quarter revenue increased 13% to $53.5 billionFourth quarter GAAP1 operating earnings were $137 million and GAAP diluted loss per share was $0.25 Fourth quarter non-GAAP operating earnings increased 24% to $560 million and non-GAAP diluted EPS increased 48% to $1.55Fourth quarter Pharmaceutical segment profit increased 12% to $504 million and Medical segment profit increased to $82 million Generated both operating cash flow and non-GAAP adjusted free cash flow of $2.8 billion and returned over $2.5 billion to shareholders in fiscal year 20232Fiscal year 2024 non-GAAP EPS guidance raised to $6.50 to $6.75, from $6.45 to $6.70DUBLIN, Ohio, Aug. 15, 2023 /PRNewswire/ -- Cardinal Health (
DUBLIN, Ohio, Aug. 9, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2023 to shareholders of record at the close of business on October 3, 2023. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business,
DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac
Revenue increased 13% to $49.6 billionGAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20Company reaffirmed fiscal year 2023 non-GAAP EPS guidanceDUBLIN, Ohio, Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 mil
Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio, Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. ("Elliott"). In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors.
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit
Believes Nominees Have the Independent Perspectives, Differentiated Real Estate Investment Experience and Shareholder-Focused Mindsets Needed to Help Reverse Lexington's Chronic Underperformance Objective and Independent New Voices are Needed in the Boardroom to Oversee Leadership Transition Process and Full Review to Determine the Right Path Forward for LXP LXP's Total Shareholder Returns Have Underperformed Proxy Peers and Industrial Peers by Nearly 500% During CEO's 18-year Tenure1 Today Land & Buildings Investment Management, LLC (together with its affiliates, "Land & Buildings"), a significant shareholder of Lexington Realty Trust ("LXP," "Lexington" or the "Company") (NYSE:LXP), an
CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company's Board of Directors, effective May 7, 2021. The Company also announced that Wayne Mackie resigned as a member of the Company's Board of Directors effective May 7, 2021. Mr. Mackie's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. "Jon is a proven leader who brings signifi
NEW YORK & LOS ANGELES--(BUSINESS WIRE)--RMG Acquisition Corp. (the “Company”) announced the nomination of Paul Williams for election at a special meeting of stockholders of the Company to serve on the board of directors of the combined company upon consummation of the previously announced merger between the Company and Romeo Systems, Inc. (“Romeo Power”). Prior to his retirement in 2018, Mr. Williams served as a Partner and Managing Director of Major, Lindsey & Africa, LLC, an executive recruiting firm, where he conducted searches for board members, CEOs and senior legal executives from 2005 to 2018. He also served as Director of Global Diversity Search, assisting legal organizati
Leerink Partners initiated coverage of Cardinal Health with a rating of Outperform and set a new price target of $125.00
Argus upgraded Cardinal Health from Hold to Buy
Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $117.00
Wells Fargo initiated coverage of Cardinal Health with a rating of Underweight and set a new price target of $96.00
Evercore ISI downgraded Cardinal Health from Outperform to In-line and set a new price target of $100.00
Citigroup initiated coverage of Cardinal Health with a rating of Neutral and set a new price target of $77.00
Robert W. Baird upgraded Cardinal Health from Neutral to Outperform and set a new price target of $94.00 from $87.00 previously
BofA Securities upgraded Cardinal Health from Underperform to Neutral and set a new price target of $80.00 from $64.00 previously
Morgan Stanley resumed coverage of Cardinal Health with a rating of Overweight and set a new price target of $76.00 from $70.00 previously
Barclays downgraded Cardinal Health from Overweight to Equal Weight